SCM
KROS icon

Superstring Capital Management’s Keros Therapeutics KROS Stock Holding History

Superstring Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-95,083
Closed -$1.5M – 53
2025
Q3 		$1.5M Buy
+95,083
New +$1.4M 1.48% 25
2024
Q3 		– Sell
-74,288
Closed -$3.39M – 38
2024
Q2 		$3.39M Buy
74,288
+40,460
+120% +$2.17M 4.28% 8
2024
Q1 		$2.24M Sell
33,828
-40,821
-55% -$2.42M 1.48% 21
2023
Q4 		$2.97M Buy
+74,649
New +$2.34M 2.12% 17

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Superstring Capital Management's KROS Position: Q4 2025 in Review

Superstring Capital Management sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 95,083 shares — an estimated $1.5M sold.

Superstring Capital Management first reported a position in KROS in Q4 2023 and held it in 4 quarters. The position peaked at $3.39M in Q2 2024. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • Superstring Capital Management reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Superstring Capital Management sold 95,083 Keros Therapeutics shares in Q4 2025, an estimated $1.5M.
  • Superstring Capital Management first reported a position in Keros Therapeutics in Q4 2023 and held it in 4 quarters.
  • Superstring Capital Management's Keros Therapeutics position peaked at $3.39M in Q2 2024.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Superstring Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.